이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Marinus Pharmaceuticals 미래 성장
Future 기준 확인 2/6
Marinus Pharmaceuticals은 연간 수입과 매출이 각각 60.5%와 42.9% 증가할 것으로 예상되고 EPS는 연간 64.6%만큼 증가할 것으로 예상됩니다.
주요 정보
60.5%
수익 성장률
64.6%
EPS 성장률
| Pharmaceuticals 수익 성장 | 27.3% |
| 매출 성장률 | 42.9% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 18 Jun 2024 |
최근 미래 성장 업데이트
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Recent updates
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 113 | -29 | 36 | N/A | 7 |
| 12/31/2025 | 58 | -79 | -59 | -73 | 11 |
| 12/31/2024 | 39 | -119 | -100 | -100 | 11 |
| 3/31/2024 | 28 | -145 | -114 | -114 | N/A |
| 12/31/2023 | 31 | -141 | -118 | -118 | N/A |
| 9/30/2023 | 31 | -134 | -113 | -113 | N/A |
| 6/30/2023 | 26 | -28 | -119 | -117 | N/A |
| 3/31/2023 | 22 | -35 | -128 | -127 | N/A |
| 12/31/2022 | 25 | -20 | -115 | -113 | N/A |
| 9/30/2022 | 20 | -14 | -115 | -113 | N/A |
| 6/30/2022 | 28 | -105 | -80 | -78 | N/A |
| 3/31/2022 | 28 | -91 | -69 | -67 | N/A |
| 12/31/2021 | 15 | -99 | -58 | -55 | N/A |
| 9/30/2021 | 15 | -88 | -52 | -50 | N/A |
| 6/30/2021 | 5 | -84 | -71 | -70 | N/A |
| 3/31/2021 | 4 | -76 | -63 | -63 | N/A |
| 12/31/2020 | 2 | -76 | -61 | -61 | N/A |
| 9/30/2020 | 0 | -74 | -61 | -61 | N/A |
| 6/30/2020 | N/A | -72 | -58 | -58 | N/A |
| 3/31/2020 | N/A | -69 | -51 | -51 | N/A |
| 12/31/2019 | N/A | -54 | -49 | -49 | N/A |
| 9/30/2019 | N/A | -49 | -42 | -42 | N/A |
| 6/30/2019 | N/A | -46 | -37 | -36 | N/A |
| 3/31/2019 | N/A | -43 | -34 | -33 | N/A |
| 12/31/2018 | N/A | -37 | -28 | -28 | N/A |
| 9/30/2018 | N/A | -31 | -23 | -23 | N/A |
| 6/30/2018 | N/A | -24 | -20 | -19 | N/A |
| 3/31/2018 | N/A | -19 | -18 | -18 | N/A |
| 12/31/2017 | N/A | -19 | N/A | -19 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -20 | N/A |
| 6/30/2017 | N/A | -22 | N/A | -24 | N/A |
| 3/31/2017 | N/A | -27 | N/A | -26 | N/A |
| 12/31/2016 | N/A | -29 | N/A | -25 | N/A |
| 9/30/2016 | N/A | -30 | N/A | -24 | N/A |
| 6/30/2016 | N/A | -29 | N/A | -23 | N/A |
| 3/31/2016 | N/A | -25 | N/A | -22 | N/A |
| 12/31/2015 | N/A | -25 | N/A | -20 | N/A |
| 9/30/2015 | N/A | -21 | N/A | -17 | N/A |
| 6/30/2015 | N/A | -18 | N/A | -14 | N/A |
| 3/31/2015 | N/A | -17 | N/A | -11 | N/A |
| 12/31/2014 | N/A | -13 | N/A | -9 | N/A |
| 9/30/2014 | N/A | -12 | N/A | -10 | N/A |
| 6/30/2014 | N/A | -12 | N/A | -8 | N/A |
| 3/31/2014 | N/A | -11 | N/A | -7 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: MRNS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: MRNS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: MRNS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: MRNS 의 수익(연간 42.9% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).
고성장 수익: MRNS 의 수익(연간 42.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: MRNS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.